Should I Buy INM? INM 2026 Analysis

Should You Buy InMed Pharmaceuticals Inc (INM) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

0.950

1 Day change

1.28%

52 Week Range

7.980

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now: price is in a clear downtrend (bearish MA stack) and there are no Intellectia buy signals to justify an aggressive entry.
The stock is trading like a micro-cap momentum/volatility name without supportive news flow; for an impatient buyer, odds favor more chop/down before any sustained rebound.
Near-term upside would likely require an event (earnings 2026-02-18) or a technical reversal back above the pivot/resistance zone; neither is confirmed today.

Technical Analysis

Trend: Bearish. Moving averages are stacked bearishly (SMA_200 > SMA_20 > SMA_5), signaling sustained downside pressure.
Momentum: MACD histogram is slightly positive (0.00243) but positively contracting, which usually indicates weakening upside momentum rather than a fresh breakout.
RSI: RSI_6 at ~26.6 suggests the stock is oversold/washed-out short term, which can support a brief bounce, but oversold alone is not a reliable buy signal against a bearish trend.
Levels: Pivot 1.077 (price 1.05 is below pivot). Support at S1 1.016 then S2 0.978; resistance at R1 1.138 then R2 1.176.
Pattern-based outlook (provided): ~-1.25% next week, ~+3.18% next month—suggesting a potential rebound later, but not a strong immediate edge.

Intellectia Proprietary Trading Signals

AI Stock Picker: no signal on given stock today.
SwingMax: No signal on given stock recently.

Positive Catalysts

- Post-market bounce (+4.95%) could hint at short-term dip-buying interest, potentially setting up a dead-cat/oversold bounce.
- Earnings scheduled 2026-02-18 (pre-market): a surprise improvement in outlook or pipeline updates could act as an event-driven catalyst.
- RSI is oversold, which can sometimes support a short, tactical rebound if buyers step in near S1/S2 support.

Neutral/Negative Catalysts

- Strong bearish trend (MA stack) and regular-session weakness (-5.66%) suggests sellers remain in control.
- No recent news in the past week: no fresh narrative catalyst to reverse sentiment.
- Micro-cap context (market cap shown ~$2.89M) often amplifies downside volatility and makes trend reversals harder to trust without signals.
- Trading flows: Hedge funds neutral (no accumulation trend); insiders neutral (no recent confidence signal).
- Congress/politician activity: No recent congress trading data available (no influential-flow confirmation).

Financial Performance

Latest quarter: 2026/Q1.
Revenue: 1,120,121, down -11.43% YoY (top-line contraction).
Net income: -1,726,899 (still a loss), improved 2.92% YoY (slight loss narrowing, but still negative).
EPS: -0.44, down -99.19% YoY (material deterioration in per-share results).
Gross margin: 31.24%, up 2.83% YoY (some margin improvement, but not enough to offset earnings weakness).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating changes or price target updates were provided in the dataset.
Wall Street-style pros (based on available info): modest gross margin improvement; upcoming earnings could reset expectations.
Wall Street-style cons: shrinking revenue, sharply worse EPS, and a dominant bearish price trend; no visible institutional/insider accumulation signals to support a bullish re-rate.

Analyst Rating

Wall Street analysts forecast INM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INM is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy

Hold